Previous 10 | Next 10 |
WALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside cha...
Summary We are checking back in on a small developmental company called Checkpoint Therapeutics, Inc. The company is planning to submit a BLA targeting two indications for its lead product candidate cosibelimab later this month. An investment analysis follows in the paragraphs below...
WALTHAM, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the submission of a Biologics License Application (“BLA”) to the U.S. Food and D...
Penny Stocks To Buy According To Analysts As the stock market continues to become more and more unpredictable, it’s increasingly important for traders to use every available tool. Whether you’re trading penny stocks or higher-priced shares, one of those tools is analyst insi...
WALTHAM, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicated institution...
WALTHAM, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding common stock....
Checkpoint Therapeutics press release ( NASDAQ: CKPT ): Q3 GAAP EPS of -$0.12 beats by $0.03 . Revenue of $0.05M (+66.7% Y/Y). For further details see: Checkpoint Therapeutics GAAP EPS of -$0.12 beats by $0.03, revenue of $0.05M
Successful completion of pre-BLA meetings in July Biologics license application (“BLA”) for both metastatic and locally advanced cutaneous squamous cell carcinoma indications expected to be submitted by January 2023 WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE...
Summary CKPT produced strong data for cosibelimab. However, data was ex-US and from an open-label trial. There's not much cash at CKPT. Checkpoint Therapeutics ( CKPT ) produced positive results from the registration trial of cosibelimab in skin cancer, however t...
Checkpoint Therapeutics press release ( NASDAQ: CKPT ): Q2 GAAP EPS of -$0.16 in-line. Revenue of $0.02M (-87.5% Y/Y) beats by $0.01M . As of June 30, 2022, Checkpoint’s cash and cash equivalents totaled $30.9 million, compared to $41.5 million at March 31, ...
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...